Figure 4

Progression-free survival of melanoma patients receiving immune biologics. Patients treated with immune biologics were monitored for recurrence from the time treatment, and grouped based on expression of MMP-23 prior to initiation of treatment (dashed line – MMP-23 composite score = 0–2; solid line – MMP-23 composite score = 3–4). P = 0.025.